Production (Stage)
Capha Pharmaceuticals Inc.
FPSUF
$0.00
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.55% | -8.85% | 5.09% | 7.25% | -5.03% |
| Depreciation & Amortization | -- | -- | -100.00% | -100.00% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.94% | -9.05% | 4.55% | 7.21% | -5.23% |
| Operating Income | 18.94% | 9.05% | -4.55% | -7.21% | 5.23% |
| Income Before Tax | 9.88% | 3.19% | 0.00% | -4.53% | 13.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.88% | 3.19% | 0.00% | -4.53% | 13.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.88% | 3.19% | 0.00% | -4.53% | 13.28% |
| EBIT | 18.94% | 9.05% | -4.55% | -7.21% | 5.23% |
| EBITDA | 18.55% | 8.85% | -5.09% | -7.25% | 5.03% |
| EPS Basic | 12.50% | 0.00% | 0.00% | 0.00% | 11.11% |
| Normalized Basic EPS | 0.00% | 0.00% | 0.00% | 20.00% | 33.33% |
| EPS Diluted | 12.50% | 0.00% | 0.00% | 0.00% | 11.11% |
| Normalized Diluted EPS | 0.00% | 0.00% | 0.00% | 20.00% | 33.33% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |